Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (N2013-02)

Complete title: NANT 2013-02: A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients with Relapsed and Refractory Neuroblastoma

Research Study Number NANT 2013-02
 
Principal Investigator Julie Park, MD
 
Phase I

Research Study Description

This study will combine three drugs: sorafenib, cyclophosphamide and topotecan.

Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigators first need to find out the highest dose of sorafenib that can be given safely together with cyclophosphamide and topotecan. This is the first study to test giving these three drugs together and will help determine the highest dose of sorafenib that can safely be given together with cyclophosphamide and topotecan to patients with resistant/relapsed neuroblastoma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number NANT 2013-02
 
Contact Julie Park, MD
 
Telephone 206/667-1212
 
E-mail
 

Keywords: Pediatric Cancers, Miscellaneous; Neuroblastoma; Neuroectodermal Tumors, Primitive (PNET); Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials